10x Genomics gets Buy rating despite insider selling and valuation concerns.

Argus Research initiated coverage on 10x Genomics with a Buy rating and a $110 price target, suggesting a 28% upside from its current price of around $85. The stock shows strong momentum, trading well above its 50-day and 200-day moving averages. However, GuruFocus warns the stock may be overvalued, estimating an intrinsic value of just $18.34, far below the market price. Insider selling is significant, with $14.4 million sold over the past year and no insider buying reported, which could signal caution despite the positive analyst outlook.

Following the recent analyst coverage and insider selling news, 10x Genomics shares continue to show resilience. On Pluang, TXG trades at USD 86.41, up 0.82% as of Sep 28, 2026 22:12 WIB, with a market cap of $11.17 billion. The typical hold time for this stock on Pluang is 93 days, indicating moderate investor engagement.